Denmark-based Novo Nordisk has unveiled plans to invest kr1.5bn ($224m) for developing a new haemophilia treatment manufacturing facility in Kalundborg.
The new 7,500m² facility is being developed to produce active pharmaceutical ingredients (APIs) for NovoSeven and future products for treating haemophilia.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Haemophilia is a bleeding disorder that affects one in 10,000 people, and people with this disorder will have either decreased, defective or absent production of blood-clotting protein.
Novo Nordisk product supply executive vice-president Henrik Wulff said: "The investment in Kalundborg underscores our long-term ambition to create and maintain jobs in Denmark.
"This year alone, we expect Novo Nordisk will create about 250 new jobs in Kalundborg, and we are always on the lookout for capable and highly skilled employees."
Novo Nordisk’s investment will create around 100 new production and engineering jobs in Kalundborg, where the firm currently employs around 2,800 people.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe new manufacturing facility is expected to begin operations in 2020.
The Kalundborg production site was established in 1969, which includes a total area of one million squared metres, and the company made ongoing investments in the site since 1999, allowing to create around 1,600 new jobs.
In March 2014, the company announced that it is increasing its drug development capacity by investing kr500m ($100m) in a new R&D facility in Bagsværd, Denmark.
Expected to be operational by late-2016, the new pilot facility will expand the company’s ability to make APIs for a growing number of diabetes drugs under development.
Image: Novo Nordisk headquarters, Denmark. Photo: courtesy of Novo Nordisk A/S.
